Eisai expects $7B sales from Biogen-partnered Alzheimer’s therapy in 2030

Eisai (OTCPK:ESAIY), the Japan-based partner of Biogen (NASDAQ:BIIB), estimated on Friday that the companies’ newly approved Alzheimer’s therapy Leqembi (lecanemab) will generate $7.4B (1T Yen) in worldwide sales in 2030.
After the FDA greenlighted the anti-amyloid monoclonal antibody under the agency’s accelerated approval for early Alzheimer’s disease, the companies launched the treatment in January at a wholesale acquisition cost of $26.5K per year.
While Medicare has restricted its use so far for those in clinical studies, Eisai’s (OTCPK:ESALF) forecast assumes broader coverage in the U.S.
The company also expects about 2.5M people globally will be eligible to receive the infusion in 2030, with prevalence in Asia/Latin America and China making up 70% of total cases.
In March, the FDA accepted the company’s marketing application for Leqembi to convert the accelerated approval into formal approval under the agency's priority review, granting July 6, 2023, as the target action date.
Read: Seeking Alpha contributor Zach Bristow issued a Buy rating on Eisai (OTCPK:ESALF) in February noting the long-term prospects of Leqembi.